| Name | Title | Contact Details |
|---|
Pathalys Pharma, Inc. is a private, late-stage clinical biopharmaceutical company committed to the development of multiple advanced therapeutics that address unmet needs in the management of end stage kidney disease (ESKD). Pathalys` initial asset is upacicalcet, a novel calcimimetic with the potential to improve the treatment of SHPT in hemodialysis patients. Beyond upacicalcet, Pathalys continues to identify other high priority needs and potential solutions for patients with ESKD. Pathalys is headquartered in Research Triangle Park, North Carolina.
MRXI Corporation is a Downers Grove, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Novel therapeutics for metabolic and endocrine disorders
Phagetech is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
API Manufacturing Company